Opus Genetics, Inc.
Opus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.
Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ird-202686xex991.htm EX-99.1 Document Exhibit 99.1 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Tria
Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 BIRD-1 trial for BEST-1 associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, and three-month topline safety and OCT structural data are expected in the second week of September 2026, with presentation at EURETINA in October. IDMC will review after Month 3.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IRD (Opus Genetics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent IRD coverage spans financial news, earnings and technology.
In the last 30 days, IRD insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($87K). The most active reporter was SCHACHLE JOSEPH K, Chief Operating Officer, with 1 filing.
The update is a near-term catalyst calendar plus cash runway confirmation, which can re-rate risk for upcoming clinical readouts.
Near-term trading focus is on the September 2026 OPGx-BEST1 Cohort 1 topline window and the Q4 2026 start of OPGx-LCA5 dosing, alongside cash runway into 2029.
The update is a concrete clinical-timeline catalyst for IRD, but it does not disclose new efficacy/safety results yet.
The update sets concrete near-term catalysts (September topline, October EURETINA) and outlines what data will drive next-step dose escalation.
Regulatory alignment reduces clinical-design uncertainty, typically supportive for biotech risk appetite.
alphai scores every news story that mentions IRD with an AI model for sentiment and relevance, and aggregates insider trades from Opus Genetics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Opus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.
6 min readOpus Genetics, Inc. (IRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ird-202686xex991.htm EX-99.1 Document Exhibit 99.1 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Tria
6 min readOpus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 BIRD-1 trial for BEST-1 associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, and three-month topline safety and OCT structural data are expected in the second week of September 2026, with presentation at EURETINA in October. IDMC will review after Month 3.
2 min readOpus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.
4 min readUS equity futures rose after the post-holiday weekend, with S&P futures up 0.4% and Nasdaq 100 up 1.1% as Mag 7 mostly gained. Chip/memory stocks rebounded ahead of Samsung Electronics’ preliminary earnings and SK Hynix’s Nasdaq listing. Other movers included BABA, DDOG, JBHT, KOS, IRD, SEER, and ZIM; macro focus includes US services PMI/ISM and Fed speakers.
7 min readThe article is promotional and not a standard news report. It says Guggenheim initiated coverage of Opus Genetics (IRD) with a “Buy” rating and a $16 price target, but provides no additional IRD financial details. It also discusses AI-related comments from Amazon’s Andy Jassy and Elon Musk, and promotes subscription offers.
6 min readBenzinga reports on five new analyst initiations for Monday, March 30, 2026. Live Nation Entertainment (LYV) received a Market Outperform rating from Citizens, along with FuboTV (FUBO). Other initiations include TSS Inc (TSSI) with a Buy rating from Needham, Netflix Inc (NFLX) with a Market Perform from Citizens, and Opus Genetics Inc (IRD) with an Overweight rating from Cantor Fitzgerald.
3 min readViatris Inc. (VTRS) and Opus Genetics, Inc. (IRD) announced the completion of a Phase 3 clinical trial for Nyxol (0.75% phentolamine ophthalmic solution), an eye drop designed to improve low-light and night vision for patients who have visual disturbances after refractive surgery. The trial's completion reduces development risk, but market reaction for involved companies will likely remain muted until the efficacy and safety data are publicly released. Positive results could create a new revenue stream for Viatris in specialty eye care and significantly impact Opus Genetics' valuation.
3 min readOpus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readDoes Opus Genetics, Inc. (IRD) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min read
